Cipla Ltd.

Cipla has received regulatory approval in India from the Drug Controller General of India (DCGI) to sell its version of Truvada as a preventive that can be given to healthy people to reduce their risk of getting HIV. Truvada is priced at Rs 2,200 for a month. The Truvada has been in use in India for about eight years now, but only for the treatment of people with the HIV infection. The big difference now is that it is used to prevent infection in healthy people.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.